Flint Animal Cancer Center

Evaluation of a Novel ITK Inhibitor in Dogs with Spontaneous T cell Lymphoma

Patient Disease:

Canine T cell Lymphoma

Study Name:

Preclinical Evaluation of a Novel ITK Inhibitor in Dogs with Spontaneous T cell Lymphoma

Purposes of the study:

  • Evaluate the safety and antitumor activity of a new drug given to dogs with T cell lymphoma

 Primary Eligibility Criteria:

  • Dogs with confirmed T cell lymphoma, newly diagnosed or relapsed

  • Must have good function of liver and kidneys, and be free of severe underlying disease

  • Owners must be able to give oral medications twice daily

  • 3 week washout from chemotherapy, 6 weeks from radiation, 72 hours from steroids

 Study Protocol:

  • Determine eligibility: Physical examination, lab work, thoracic radiographs

  • Day 0: Physical exam, study blood collection, tumor biopsy, administer study drug

  • Week 1: Physical examination, lab work, study blood collection for 24 hours (overnight hospital stay may be necessary)

  • Week 2: Physical exam, lab work, study blood collection, tumor biopsy

  • Weeks 3 & 4 and then every other week until disease progression: Physical exam, lab work, study blood collection

 Owner Responsibilities:

  • To make and keep all appointments for the study protocol

  • Administer oral medications at home

  • Complete daily log to document drug administration and side effects

 Financial Incentives:

  • Study will cover all costs related to the study as well as the treatment of any side effects that occur due to the study drug

  • A credit of $1000 will be given upon completion of the study to put towards continued treatment

  • The owner is responsible for costs of tests needed to confirm study eligibility


If you have further questions about any of our clinical trials, please submit an online consulting form. Your consult will then be directed to an appropriate oncology clinician. Requests are typically returned within 5 business days.